Finance

Lists
Q2 2027 earnings • released • EPS miss -12.09% • Revenue beat +1.79%
See results
TORNTPHARM:NSE
Torrent Pharmaceuticals Ltd
₹4,579.50
+0.65%
(+29.50) 1D
Oct 27, 12:09:25 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for TORNTPHARM...
Open
₹4,547.90
High
₹4,649.90
Low
₹4,547.80
Mkt. cap
1.74T
Avg. vol.
343.47K
Volume
115.38K
Dividend
0.83%
Quarterly dividend
₹9.51
Ex-dividend date
May 29, 2026
P/E ratio
73.10
52-wk high
₹5,250.00
52-wk low
₹3,532.60
EPS
₹62.60
Shares outstanding
170.00M
No. of employees
18K
Open
₹4,547.90
High
₹4,649.90
Low
₹4,547.80
Mkt. cap
1.74T
Avg. vol.
343.47K
Volume
115.38K
Dividend
0.83%
Quarterly dividend
₹9.51
Ex-dividend date
May 29, 2026
P/E ratio
73.10
52-wk high
₹5,250.00
52-wk low
₹3,532.60
EPS
₹62.60
Shares outstanding
170.00M
No. of employees
18K
News stories
From web sources and news partners
Profile
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics. Wikipedia
About Torrent Pharmaceuticals Ltd
CEO-
Employees18.3K
Founded1959
HeadquartersAhmedabad, Gujarat, India
SectorPharmaceutical industry
Last report
Oct 23, 2026
Fiscal period
Q2 2027
₹14.24 / ₹16.20
-12.09%miss
Revenue / Est. (INR)
49.79B / 48.91B
+1.79%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
33.03B
41.97B
49.21B
49.79B
Cost of goods sold
7.99B
10.15B
11.63B
12.24B
Cost of revenue
7.99B
10.15B
11.63B
12.24B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.51B
8.48B
8.93B
8.95B
Operating expense
16.22B
23.34B
26.87B
26.98B
Total operating expenses
24.21B
33.49B
38.50B
39.22B
Operating income
8.82B
8.48B
10.71B
10.57B
Other non operating income
-130.00M
794.40M
-120.00M
-100.00M
EBT including unusual items
8.14B
5.29B
7.33B
7.37B
EBT excluding unusual items
8.24B
5.47B
7.54B
7.47B
Income tax expense
1.79B
1.65B
1.67B
2.03B
Effective tax rate
21.99%
31.18%
22.78%
27.54%
Other operating expenses
7.65B
9.78B
12.01B
11.94B
Net income
6.35B
3.89B
5.66B
5.34B
Net profit margin
19.22%
9.28%
11.50%
10.72%
Earnings per share
19.00
12.85
15.30
14.24
Interest and investment income
-
384.30M
-
-
Interest expense
-450.00M
-2.36B
-3.05B
-3.00B
Net interest expenses
-450.00M
-1.97B
-3.05B
-3.00B
Depreciation and amortization charges
2.06B
5.08B
5.93B
6.09B
EBITDA
10.69B
11.12B
13.35B
16.58B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps